This inventor holds 1 USPTO granted patent. Top assignee: Zeneca Limited. Active years: 1997.
Company Filing History:
Years Active: 1997
Title: Michael Samuel Rose: Innovator in Tumor-Associated Antigens
Introduction
Michael Samuel Rose is a notable inventor based in Wilmslow, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target tumor-associated antigens. His work is crucial in advancing cancer research and treatment.
Latest Patents
Michael Samuel Rose holds a patent for "Antibodies recognizing tumor associated antigen CA 55.1." This patent involves antibodies that recognize a tumor-related antigen designated CA55.1, specifically hybridoma 55.1, which has been deposited as ECACC deposit no. 93081901. The complementarity determining regions of these antibodies have specific sequences that enhance their effectiveness in targeting cancer cells.
Career Highlights
Throughout his career, Michael has focused on innovative solutions in the medical field. His work has contributed to the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes through scientific advancements.
Collaborations
Michael has collaborated with esteemed colleagues, including Christopher Boot and Clive Graham Copley. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of biotechnology.
Conclusion
Michael Samuel Rose's contributions to the development of tumor-associated antibodies highlight his role as an innovator in the medical field. His work continues to influence cancer research and treatment, making a lasting impact on healthcare.